MyoVista wavECG vs Triomics
These serve two rooms, an ECG review desk and a clinical trial office.
HeartSciences describes MyoVista Insights as an ECG management system that centralizes data from 12-lead ECG devices and third-party AI-ECG models, with an algorithm marketplace and longitudinal ECG comparison. Its site says the company's AI-ECG products are not commercially available in the United States, and the homepage links an Epic showroom listing. A business combination with Fortitude Mining Holdings is expected to close in the fourth quarter of 2026, per the company's release.
Triomics sells to cancer centers. PRISM screens upcoming patients against every active trial each night and hands coordinators a cited worklist. Memorial Sloan Kettering announced a deployment in November 2025 and discloses institutional financial interests in Triomics. The vendor says it runs inside Epic, OncoEMR and iKnowMed and is approved on the Epic App Marketplace. openFDA's 510(k) database holds no Triomics record, and the vendor pages read make no FDA claim.
Decision support · Reviewed November 2, 2026
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
Triomics
by triomics inc.
Oncology AI agents that match patients to clinical trials, prepare visits and curate cancer registries from notes, reports and faxes.
When to pick each one
MyoVista wavECG
- Describes multi-device ECG management software
- Epic showroom listing linked on homepage
Triomics
- Screens upcoming patients against active trials nightly
- Approved on the Epic App Marketplace (vendor)
- Memorial Sloan Kettering announced a deployment
Score
Each row shows points earned of points available under the published rubric.
MyoVista wavECG
31of 100
Triomics
12of 100
| Dimension | MyoVista wavECG | Triomics | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 6 / 10 | 0 / 10 | +6 |
| EHR integrations (count) | 1.7 / 5.6 | 2.8 / 5.6 | -1.1 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 1.9 / 4.8 | 3.4 / 4.8 | -1.4 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 0 / 21 | 0 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Triomics
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request and synthetic-data sandbox offered. |
Evidence
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
Triomics
FDA decisions
No FDA decision cited in our research as of November 2, 2026.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | MyoVista wavECG | Triomics |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Epic | Epic, OncoEMR, iKnowMed, Cerner |
| Founded | n/a | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.